Paclitaxel as the initial treatment of multiple myeloma: An Eastern Cooperative Oncology Group study (E1A93)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 553-556

  Miller, Harry J ^a,d   Leong, Traci ^b   Khandekar, Janardan D ^a   Greipp, Philip R ^c   Gertz, Morie A ^c   Kyle, Robert A ^c  

^a EVANSTON HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d NONE   (United States)

Author keywords

Eastern Cooperative Oncology Group; Multiple myeloma; Paclitaxel

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; NEUTROPENIA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 0031770423     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00005     Document Type: Article

References (14)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;22:665-7.
2. Rowinsky EK, Cazenave LA, Donehower RC. Taxol a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
3. Wilson C, Koster W, Dietz G, et. al. Invitro effect of paclitaxel in combination with cytotoxic agents on two different human myeloma cell lines [Abstract]. Blood 1994;84:182a.
4. Nguyen MH, Treon SP, Broitman SA. In-vitro studies in support of taxol for the treatment of multiple myeloma [Abstract]. Blood 1994;84:179a.
5. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. JAMA 1969;208:1680-5.
6. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy vs melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
7. MacLennan ICM, Chapman C, Dunn J, et al. Combination chemotherapy with ABCM vs melphalan for treatment of myelomatosis. Lancet 1992;339:200-5.
8. Oken MM, Tsiatis A, Abramson N, Glick J. Evaluation of intensive (VBMCP vs standard CMP) therapy for multiple myeloma. Proceedings of the American Society of Clinical Oncology 1987;6:203.
9. a2) in multiple myeloma: 3-year follow-up [Abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:1062.
10. Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R. Primary therapy of multiple myeloma with paclitaxel (taxol). University of Texas M.D. Anderson Cancer Center, Houston. Ann Oncol 1994;20:757-9.
11. Gelman K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344:1267-71.
12. α2) or high-dose cyclophosphamide to vbmcp to treat multiple myeloma: results from an ECOG phase III trial. The Virginia Piper Cancer Institute and the Eastern Cooperative Oncology Group (ECOG), Brookline, MA [Abstract]. Blood 1995;86:20.
13. Leong T, Silva F. Analysis of EST 9486: phase III study of VBMCP chemotherapy with or without intensification or alpha-2 interferon for previously untreated multiple myeloma. Brookline, MA: Eastern Cooperative Oncology Group, Technical Report 854E, May 1996.
14. Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma, results of Eastern Cooperative Oncology Group study E2479. Cancer 1997;79:1561-7.